Purchase this article with an account.
Barbara M. Wirostko, Hiroshi Umeno, Henry Hsu, Muralitharan Kengatharan; Safety and Efficacy of a Novel Topical Rho Kinase Inhibitor ATS8535 in vivo. Invest. Ophthalmol. Vis. Sci. 2012;53(14):5079.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To determine tolerability and intraocular pressure (IOP) lowering efficacy of a novel topical Rho Kinase (ROCK) inhibitor ATS8535 in unanesthetized normotensive cynomolgus monkeys (NHP) and New Zealand White rabbits (NZW).
NZW rabbits (5/group) received a single dose OD topically with ATS8535 (0.008%, 0.08% & 0.2% ophthalmic formulation). NHPs (3-4/group) received a single topical dose OS of ATS8535 (0.008%, 0.08% & 0.2%). IOP was measured every 2hrs from baseline to 10hrs (NHP) or 12hrs (NZW) post dose. In both studies the contralateral control eye received saline. In a separate study, ocular tolerability was assessed in NZW (4 eyes/group) at daily doses of 0.08% to 0.6% given BID for 3 days with safety assessments that included gross exams, eyelid closure, pupil size and biomicroscopy (corneal opacity and congestion of conjunctiva and iris).
A decline in IOP was observed at 2 hrs post dose in both species with a difference in IOP vs control noted through10 hrs (NHP) and 12hrs (NZW) after instillation of ATS8535. Maximal IOP reduction following single dose administration of ATS8535 was -5.0 mmHg at 0.2% (NHP) and was -7.0mmHg at 0.08% (NZW) between 2-4 hrs post dosing. The mean IOP at baseline for both NHP and NZW was approximately 21.5-22.5 mmHg and did not change significantly over the monitoring period. No significant ocular abnormalities were observed after BID ocular administration in NZW for 3 days other than mild, transient and reversible conjunctival congestion (hyperemia).
ATS 8535 is effective in lowering IOP topically after a single dose in NZW and NHPs. ATS8535 has a rapid onset of action. Ocular tolerability profile was favorable throughout the study. ATS8535 is a viable therapeutic compound to potentially lower elevated IOP in humans.
This PDF is available to Subscribers Only